share_log

HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9

Moomoo 24/7 ·  Mar 21 11:27

HC Wainwright & Co. analyst Emily Bodnar maintains MiNK Therapeutics (NASDAQ:INKT) with a Buy and lowers the price target from $10 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment